Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4538-37: Nivolumab plus oxaliplatin-based chemotherapy in advanced HER2-negative gastric cancer
jRCT2080223111Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in gastric cancer (GC) and esophagogastric junction cancer comparing Nivolumab + oxaliplatin-based chemotherapy with Placebo + oxaliplatin-based chemotherapy (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Feb 2016; status: completed.
02
Drugs
03
Conditions
gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on jRCT2080223111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223111.